<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34480080</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2045-2322</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Sep</Month>
              <Day>03</Day>
            </PubDate>
          </JournalIssue>
          <Title>Scientific reports</Title>
          <ISOAbbreviation>Sci Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Aberrant activation of the Hedgehog signalling pathway in squamous cell carcinoma of the vulva as a potential target for cancer therapy.</ArticleTitle>
        <Pagination>
          <StartPage>17665</StartPage>
          <MedlinePgn>17665</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">17665</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-021-96940-1</ELocationID>
        <Abstract>
          <AbstractText>In a previous study, we showed that the Hedgehog (Hh) signalling pathway is aberrantly activated in vulval squamous cell carcinoma (VSCC). In this study, we further validated our findings on a prospective cohort of primary VSCC cases, where immunohistochemical staining confirmed that key Hh pathway components were overexpressed in VSCC compared to normal vulval epithelium. We also undertook a series of in vitro studies to determine the extent of Hh pathway activation in VSCC-derived cell lines, and examine the consequences of pathway inhibition on the growth of these cells. We found that of six cell lines tested, four displayed elevated baseline Hh pathway activity that was dependent on SHH ligand, or in one case, a PTCH1 gene mutation. Hh signalling appeared necessary to sustain cell growth, as SHH ligand depletion with Robotikinin or SMO inhibition, either with chemical inhibitors (Itraconazole or LDE-225) or SMO-specific siRNA, attenuated GLI1 activity and cell proliferation in both monolayer and organotypic raft culture. Furthermore, treatment of Hh-dependent cell lines with SMO inhibitors sensitised cells to Cisplatin. Findings from our study offer us the opportunity to explore further the development of targeted chemotherapy for women with VSCC driven by aberrant Hh activation.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yap</LastName>
            <ForeName>Jason K W</ForeName>
            <Initials>JKW</Initials>
            <AffiliationInfo>
              <Affiliation>Birmingham Cancer Research UK Cancer Centre, Institute of Cancer and Genomic Sciences, University of Birmingham, Vincent Drive, Edgbaston, Birmingham, B15 2TT, UK. j.yap@bham.ac.uk.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Pan Birmingham Gynaecological Cancer Centre, Birmingham City Hospital, Dudley Road, Birmingham, B18 7QH, UK. j.yap@bham.ac.uk.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Uddin</LastName>
            <ForeName>Khalil</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Birmingham Cancer Research UK Cancer Centre, Institute of Cancer and Genomic Sciences, University of Birmingham, Vincent Drive, Edgbaston, Birmingham, B15 2TT, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pounds</LastName>
            <ForeName>Rachel</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Birmingham Cancer Research UK Cancer Centre, Institute of Cancer and Genomic Sciences, University of Birmingham, Vincent Drive, Edgbaston, Birmingham, B15 2TT, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Pan Birmingham Gynaecological Cancer Centre, Birmingham City Hospital, Dudley Road, Birmingham, B18 7QH, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>O'Neill</LastName>
            <ForeName>Danielle</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Birmingham Cancer Research UK Cancer Centre, Institute of Cancer and Genomic Sciences, University of Birmingham, Vincent Drive, Edgbaston, Birmingham, B15 2TT, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kehoe</LastName>
            <ForeName>Sean</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Birmingham Cancer Research UK Cancer Centre, Institute of Cancer and Genomic Sciences, University of Birmingham, Vincent Drive, Edgbaston, Birmingham, B15 2TT, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Pan Birmingham Gynaecological Cancer Centre, Birmingham City Hospital, Dudley Road, Birmingham, B18 7QH, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ganesan</LastName>
            <ForeName>Raji</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Birmingham Women's NHS Foundation Trust, Mindelsohn Way, Edgbaston, Birmingham, B15 2TG, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dawson</LastName>
            <ForeName>Christopher W</ForeName>
            <Initials>CW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology &amp; Infection, Warwick Medical School, University of Warwick, Coventry, CV4 7AL, UK. C.Dawson.3@warwick.ac.uk.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>09</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Sci Rep</MedlineTA>
        <NlmUniqueID>101563288</NlmUniqueID>
        <ISSNLinking>2045-2322</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053823">Hedgehog Proteins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002294" MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053823" MajorTopicYN="N">Hedgehog Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015603" MajorTopicYN="N">Keratinocytes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014846" MajorTopicYN="N">Vulvar Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>2</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34480080</ArticleId>
        <ArticleId IdType="pmc">PMC8417215</ArticleId>
        <ArticleId IdType="doi">10.1038/s41598-021-96940-1</ArticleId>
        <ArticleId IdType="pii">10.1038/s41598-021-96940-1</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Cancer Research UK (CRUK). Vulval Cancer Incidence Statistics. 2014. http://www.cancerresearchuk.org/health-professional/cancer-statistics-for-the-uk.</Citation>
        </Reference>
        <Reference>
          <Citation>Royal College of Obstetrician and Gynaecologist. Guidelines for the Diagnosis and Management of Vulval Cancer (2014).</Citation>
        </Reference>
        <Reference>
          <Citation>Yap J, et al.  Current insights into the aetiology, pathobiology, and management of local disease recurrence in squamous cell carcinoma of the vulva. BJOG. 2017;124(6):946–954. doi: 10.1111/1471-0528.14560.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1471-0528.14560</ArticleId>
            <ArticleId IdType="pubmed">28081287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu P, et al.  Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 2009;8(8):627–644. doi: 10.1038/nrd2926.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrd2926</ArticleId>
            <ArticleId IdType="pmc">PMC3142564</ArticleId>
            <ArticleId IdType="pubmed">19644473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, et al.  The role of the PI3K/Akt/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses. Mol. Cancer. 2015;14:87. doi: 10.1186/s12943-015-0361-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-015-0361-x</ArticleId>
            <ArticleId IdType="pmc">PMC4498560</ArticleId>
            <ArticleId IdType="pubmed">26022660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zieba S, et al.  Somatic mutation profiling of vulval cancer: Exploring therapeutic targets. Gynecol. Oncol. 2018;150(3):552–561. doi: 10.1016/j.ygyno.2018.06.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2018.06.026</ArticleId>
            <ArticleId IdType="pubmed">29980281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trietsch MD, et al.  CDKN2A(p16) and HRAS are frequently mutated in vulval squamous cell carcinoma. Gynecol. Oncol. 2014;135(1):149–155. doi: 10.1016/j.ygyno.2014.07.094.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2014.07.094</ArticleId>
            <ArticleId IdType="pubmed">25072932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palisoul ML, et al.  Identification of molecular targets in vulval cancers. Gynecol. Oncol. 2017;146(2):305–313. doi: 10.1016/j.ygyno.2017.05.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2017.05.011</ArticleId>
            <ArticleId IdType="pubmed">28536037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yap J, et al.  Under expression of the Sonic Hedgehog receptor, Patched1 (PTCH1), is associated with an increased risk of local recurrence in squamous cell carcinoma of the vulva arising on a background of Lichen Sclerosus. PLoS ONE. 2018;13(10):e0206553. doi: 10.1371/journal.pone.0206553.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0206553</ArticleId>
            <ArticleId IdType="pmc">PMC6209322</ArticleId>
            <ArticleId IdType="pubmed">30379908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pasca di Magliano M, Hebrok M. Hedgehog signalling in cancer formation and maintenance. Nat. Rev. Cancer. 2003;3(12):903–911. doi: 10.1038/nrc1229.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc1229</ArticleId>
            <ArticleId IdType="pubmed">14737121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xuan YH, et al.  Enhanced expression of hedgehog signaling molecules in squamous cell carcinoma of uterine cervix and its precursor lesions. Mod. Pathol. 2006;19(8):1139–1147. doi: 10.1038/modpathol.3800600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/modpathol.3800600</ArticleId>
            <ArticleId IdType="pubmed">16778829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Northcott PA, et al.  Medulloblastomics: The end of the beginning. Nat. Rev. Cancer. 2012;12:818–834. doi: 10.1038/nrc3410.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3410</ArticleId>
            <ArticleId IdType="pmc">PMC3889646</ArticleId>
            <ArticleId IdType="pubmed">23175120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pasca di Magliano M, Hebrok M. Hedgehog signalling in cancer formation and maintenance. Nat. Rev. Cancer. 2003;3:903–911. doi: 10.1038/nrc1229.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc1229</ArticleId>
            <ArticleId IdType="pubmed">14737121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ng JM, Curran T. The Hedgehog's tale: developing strategies for targeting cancer. Nat. Rev. Cancer. 2011;11:493–501. doi: 10.1038/nrc3079.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3079</ArticleId>
            <ArticleId IdType="pmc">PMC3576812</ArticleId>
            <ArticleId IdType="pubmed">21614026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koike C, et al.  Introduction of wild-type patched gene suppresses the oncogenic potential of human squamous cell carcinoma cell lines including A431. Oncogene. 2002;21(17):2670. doi: 10.1038/sj.onc.1205370.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1205370</ArticleId>
            <ArticleId IdType="pubmed">11965540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stanton BZ, et al.  A small molecule that binds Hedgehog and blocks its signalling in human cells. Nat. Chem. Biol. 2009;5(3):154–156. doi: 10.1038/nchembio.142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.142</ArticleId>
            <ArticleId IdType="pmc">PMC2770933</ArticleId>
            <ArticleId IdType="pubmed">19151731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pounds R, et al.  Repurposing itraconazole for the treatment of cancer. Oncol. Lett. 2017;14(3):2587. doi: 10.3892/ol.2017.6569.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2017.6569</ArticleId>
            <ArticleId IdType="pmc">PMC5588108</ArticleId>
            <ArticleId IdType="pubmed">28927025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan S, et al.  Discovery of NVP-LDE225, a potent and selective smoothened antagonist. ACS Med. Chem. Lett. 2010;1(3):130. doi: 10.1021/ml1000307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/ml1000307</ArticleId>
            <ArticleId IdType="pmc">PMC4007689</ArticleId>
            <ArticleId IdType="pubmed">24900187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanna A, Shevde LA. Hedgehog signaling: Modulation of cancer properties and tumor microenvironment. Mol. Cancer. 2016;15:24. doi: 10.1186/s12943-016-0509-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-016-0509-3</ArticleId>
            <ArticleId IdType="pmc">PMC4797362</ArticleId>
            <ArticleId IdType="pubmed">26988232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sims-Mourtada J, et al.  Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene. 2007;26(38):5674. doi: 10.1038/sj.onc.1210356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1210356</ArticleId>
            <ArticleId IdType="pubmed">17353904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sekulic A, et al.  Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17(1):332. doi: 10.1186/s12885-017-3286-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-017-3286-5</ArticleId>
            <ArticleId IdType="pmc">PMC5433030</ArticleId>
            <ArticleId IdType="pubmed">28511673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J, et al.  Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell. 2010;17(4):388–399. doi: 10.1016/j.ccr.2010.02.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2010.02.027</ArticleId>
            <ArticleId IdType="pmc">PMC4039177</ArticleId>
            <ArticleId IdType="pubmed">20385363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leonard S, et al.  Over-expression of DNMT3A predicts the risk of recurrent vulval squamous cell carcinomas. Gynecol. Oncol. 2016;143(2):414–420. doi: 10.1016/j.ygyno.2016.09.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2016.09.001</ArticleId>
            <ArticleId IdType="pubmed">27623253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirsch FR, et al.  Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. 2003;21(20):3798–3807. doi: 10.1200/JCO.2003.11.069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2003.11.069</ArticleId>
            <ArticleId IdType="pubmed">12953099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allred DC, et al.  Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 1998;11(2):155–168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9504686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carpenter PM, et al.  UCI-VULV-1, a vulval squamous carcinoma cell line. Gynecol. Oncol. 1995;57(2):191–198. doi: 10.1006/gyno.1995.1124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/gyno.1995.1124</ArticleId>
            <ArticleId IdType="pubmed">7729733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grenman SE, et al.  Phenotypic characterization, karyotype analysis and in vitro tamoxifen sensitivity of new ER-negative vulval carcinoma cell lines, UM-SCV-1A and UM-SCV-1B. Int. J. Cancer. 1990;45(5):920–927. doi: 10.1002/ijc.2910450524.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.2910450524</ArticleId>
            <ArticleId IdType="pubmed">2335395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raitanen M, et al.  Characterization of 10 vulval carcinoma cell lines by karyotyping, comparative genomic hybridization and flow cytometry. Gynecol. Oncol. 2004;93(1):155–163. doi: 10.1016/j.ygyno.2003.12.033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2003.12.033</ArticleId>
            <ArticleId IdType="pubmed">15047230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rasmussen C, Thomas-Virnig C, Allen-Hoffmann BL. Classical human epidermal keratinocyte cell culture. Methods Mol. Biol. 2013;945:161–175. doi: 10.1007/978-1-62703-125-7_11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-62703-125-7_11</ArticleId>
            <ArticleId IdType="pubmed">23097107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dawson CW, Young LS. In vitro assays to study epithelial cell differentiation. Methods Mol. Biol. 2001;174:173–180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11357641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morris MA, et al.  The EBV-encoded oncoprotein, LMP1, induces an epithelial-to-mesenchymal transition (EMT) via its CTAR1 domain through integrin-mediated ERK-MAPK signalling. Cancers (Basel) 2018;10(5):130. doi: 10.3390/cancers10050130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers10050130</ArticleId>
            <ArticleId IdType="pmc">PMC5977103</ArticleId>
            <ArticleId IdType="pubmed">29723998</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
